Highly sensitive electrochemical detection of circulating tumor DNA based on thin-layer MoS2/graphene composites

RSC Advances ◽  
2016 ◽  
Vol 6 (27) ◽  
pp. 22673-22678 ◽  
Author(s):  
Yilan Chu ◽  
Bin Cai ◽  
Ye Ma ◽  
Minggang Zhao ◽  
Zhizhen Ye ◽  
...  
Keyword(s):  
Thin Layer ◽  
Electrochemical Sensor ◽  
Molybdenum Disulfide ◽  
Electrochemical Detection ◽  
Ultrasonic Method ◽  
Hydrothermal Process ◽  
Circulating Tumor Dna ◽  
Label Free ◽  
Highly Sensitive ◽  
Tumor Dna

By integrating thin-layer molybdenum disulfide (MoS2) and graphene through a hydrothermal process and an ultrasonic method, a label-free, amplification-free and ultrasensitive circulating tumor DNA electrochemical sensor was made.

A graphene oxide coated gold nanostar based sensing platform for ultrasensitive electrochemical detection of circulating tumor DNA

2020 ◽  
Vol 12 (4) ◽  
pp. 440-447 ◽  
Author(s):  
Mahbubur Rahman ◽  
Daxiang Cui ◽  
Shukui Zhou ◽  
Amin Zhang ◽  
Di Chen
Keyword(s):  
Graphene Oxide ◽  
Gastric Carcinoma ◽  
Electrochemical Reduction ◽  
Electrochemical Detection ◽  
Peripheral Blood ◽  
High Performance ◽  
Circulating Tumor Dna ◽  
Electrochemical Sensing ◽  
Sensing Platform ◽  
Tumor Dna

A high-performance electrochemical sensing platform inspired by a functional ‘green’ electrochemical reduction pathway was developed to identify and detect circulating tumor DNA (ctDNA) of gastric carcinoma in peripheral blood.

Label-free fluorescent catalytic biosensor for highly sensitive and selective detection of the ferrous ion in water samples using a layered molybdenum disulfide nanozyme coupled with an advanced chemometric model

The Analyst ◽  
2016 ◽  
Vol 141 (5) ◽  
pp. 1822-1829 ◽  
Author(s):  
Jie Hu ◽  
Qianfen Zhuang ◽  
Yong Wang ◽  
Yongnian Ni
Keyword(s):  
Molybdenum Disulfide ◽  
Water Samples ◽  
Catalytic Effect ◽  
Ferrous Ion ◽  
Selective Detection ◽  
Label Free ◽  
Highly Sensitive

The synergistically enhanced catalytic effect of a Fe2+/molybdenum disulfide (MoS2) nanosheet was exploited to construct a nanozyme biosensor for Fe2+.

An aptamer based voltammetric biosensor for endotoxins using a functionalized graphene and molybdenum disulfide composite as a new nanocarrier

The Analyst ◽  
2019 ◽  
Vol 144 (4) ◽  
pp. 1253-1259 ◽  
Author(s):  
Yonghua Yuan ◽  
Linlin Li ◽  
Min Zhao ◽  
Jing Zhou ◽  
Zhihui Chen ◽  
...  
Keyword(s):  
Molybdenum Disulfide ◽  
Functionalized Graphene ◽  
Label Free ◽  
Highly Sensitive

This work describes a label-free aptasensor for highly sensitive endotoxin detection using a functionalized graphene and molybdenum disulfide composite for amplification.

A silicon-based electrochemical sensor for highly sensitive, specific, label-free and real-time DNA detection

2013 ◽  
Vol 24 (44) ◽  
pp. 444012 ◽  
Author(s):  
Yuanyuan Guo ◽  
Shao Su ◽  
Xinpan Wei ◽  
Yiling Zhong ◽  
Yuanyuan Su ◽  
...  
Keyword(s):  
Electrochemical Sensor ◽  
Real Time ◽  
Dna Detection ◽  
Label Free ◽  
Highly Sensitive ◽  
Silicon Based ◽  
Specific Label

scholarly journals A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker

2016 ◽  
Vol 62 (8) ◽  
pp. 1129-1139 ◽  
Author(s):  
Sonia Garrigou ◽  
Geraldine Perkins ◽  
Fanny Garlan ◽  
Corinne Normand ◽  
Audrey Didelot ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Genetic Material ◽  
Surrogate Marker ◽  
Digital Pcr ◽  
Tumor Stage ◽  
Circulating Tumor Dna ◽  
Tumor Evolution ◽  
Highly Sensitive ◽  
Tumor Dna

Abstract BACKGROUND Circulating tumor DNA (ctDNA) has emerged as a good candidate for tracking tumor dynamics in different cancer types, potentially avoiding repeated tumor biopsies. Many different genes can be mutated within a tumor, complicating procedures for tumor monitoring, even with highly sensitive next-generation sequencing (NGS) strategies. Droplet-based digital PCR (dPCR) is a highly sensitive and quantitative procedure, allowing detection of very low amounts of circulating tumor genetic material, but can be limited in the total number of target loci monitored. METHODS We analyzed hypermethylation of 3 genes, by use of droplet-based dPCR in different stages of colorectal cancer (CRC), to identify universal markers for tumor follow-up. RESULTS Hypermethylation of WIF1 (WNT inhibitory factor 1) and NPY (neuropeptide Y) genes was significantly higher in tumor tissue compared to normal tissue, independently of tumor stage. All tumor tissues appeared positive for one of the 2 markers. Methylated ctDNA (MetctDNA) was detected in 80% of metastatic CRC and 45% of localized CRC. For samples with detectable mutations in ctDNA, MetctDNA and mutant ctDNA (MutctDNA) fractions were correlated. During follow-up of different stage CRC patients, MetctDNA changes allowed monitoring of tumor evolution. CONCLUSIONS These results indicate that MetctDNA could be used as a universal surrogate marker for tumor follow-up in CRC patients, and monitoring MetctDNA by droplet-based dPCR could avoid the need for monitoring mutations.

scholarly journals Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2914 ◽  
Author(s):  
Alessandra Sacco ◽  
Laura Forgione ◽  
Marianeve Carotenuto ◽  
Antonella De Luca ◽  
Paolo A. Ascierto ◽  
...  
Keyword(s):  
Residual Disease ◽  
Circulating Tumor Dna ◽  
Resistance Mechanisms ◽  
Prognostic Information ◽  
Skin Cancers ◽  
Highly Sensitive ◽  
Ctdna Analysis ◽  
Next Generation Sequencing Ngs ◽  
Tumor Dna

Malignant melanoma accounts for about 1% of all skin cancers, but it causes most of the skin cancer-related deaths. Circulating tumor DNA (ctDNA) testing is emerging as a relevant tool for the diagnosis and monitoring of cancer. The availability of highly sensitive techniques, including next generation sequencing (NGS)-based panels, has increased the fields of application of ctDNA testing. While ctDNA-based tests for the early detection of melanoma are not available yet, perioperative ctDNA analysis in patients with surgically resectable melanoma offers relevant prognostic information: i) the detection of ctDNA before surgery correlates with the extent and the aggressiveness of the disease; ii) ctDNA testing after surgery/adjuvant therapy identifies minimal residual disease; iii) testing ctDNA during the follow-up can detect a tumor recurrence, anticipating clinical/radiological progression. In patients with advanced melanoma, several studies have demonstrated that the analysis of ctDNA can better depict tumor heterogeneity and provides relevant prognostic information. In addition, ctDNA testing during treatment allows assessing the response to systemic therapy and identifying resistance mechanisms. Although validation in prospective clinical trials is needed for most of these approaches, ctDNA testing opens up new scenarios in the management of melanoma patients that could lead to improvements in the diagnosis and therapy of this disease.

Sign in / Sign up

Export Citation Format

Share Document